Cowen reiterated an Outperform rating and $150.00 price target on Celgene (NASDAQ: CELG) following the company's announcement that the Ph ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE